Please assess the completion status of the following clinical trial:

Trial Title: Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>= 1 year of infertility~* \< 38 years old~* Normal HSG~* Normal Semen analysis (Count \>= 20 million/ motility \> 50%/ Kruger morph \> 14%.~* Regular menses~* Willingness to sign informed consent for study randomization~* Willingness to participate in 8 months of non-IVF will he him treatment.~Exclusion Criteria:~* Abnormal semen analysis~* Abnormal HSG~* Baseline FSH/E2 within normal age specific criteria~* Medical condition that would contraindicate pregnancy, ovulation induction or general anesthesia~* Family history of significant genetic disease, or factor V leiden thrombophilia~* Inability to present for monitoring visits~* Inability to follow medication instruction~* Desire to undergo other fertility treatments before completing eight months of this trial

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 37 Years
- Healthy Volunteers: t

Study Arms:
- DHEA (Type: EXPERIMENTAL): Dehydroepiandrosterone (DHEA) administered at a dose of 25 mg tid po. DHEA is a weak androgen produced naturally by the adrenal in men and women. DHEA production is diminished with increasing age. Peak levels of DHEA occur in the late teenage years.
- Placebo (Type: PLACEBO_COMPARATOR): Blinded placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).